Pharma BD Deal Intelligence
A costly stumble for Lilly: $300M upfront plus $80M equity ($380M total) for Foghorn's chromatin-regulator platform and lead asset FHD-286, which was paused in AML in January 2022 over a differentiation-syndrome signal.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly is paying Foghorn Therapeutics $300 million in cash and $80 million for stock, plus up to $1.3 billion in milestone payments, in a five-program…
Eli Lilly and Foghorn Therapeutics announced a strategic collaboration to discover, develop and commercialize novel oncology therapies leveraging Foghorn's…
Foghorn discontinued independent development of FHD-286 in combination with decitabine in relapsed/refractory AML after the Phase 1 readout did not meet its…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Eli Lilly (via Loxo Oncology at Lilly) and Foghorn Therapeutics entered a strategic oncology collaboration announced December 13, 2021 (agreement signed December 10, 2021), built on Foghorn's Gene Traffic Control chromatin-regulator platform. Foghorn received $300M cash upfront plus an $80M equity investment ($380M total) and is eligible for up to $1.3B in milestones plus tiered royalties. The pact is structured as a U.S. 50/50 co-development and co-commercialization agreement on Foghorn's selective SMARCA2 (BRM) oncology program and an additional undisclosed oncology target, plus three discovery programs. The collaboration cleared HSR review and became effective in January 2022, when Foghorn received the upfront. The original anchor clinical asset, FHD-286 (a SMARCA2/SMARCA4 dual inhibitor), was paused in AML in January 2022 over a differentiation-syndrome signal and, after the Phase 1 decitabine-combination readout missed Foghorn's internal efficacy threshold, Foghorn discontinued independent FHD-286 AML development on December 16, 2024. The collaboration's lead asset is now FHD-909 (LY4050784), a first-in-class oral selective SMARCA2 inhibitor that dosed its first Phase 1 patient on October 10, 2024 in SMARCA4-mutated solid tumors (NSCLC primary).
30K US cases/yr · $12.0B Global precision oncology small-molecule market (2021) · ~10% NSCLC SMARCA4 mutation rate
The BAF (BRG1/BRM-associated factor) chromatin remodeling complex is mutated in approximately 20% of all human cancers, with SMARCA4 (BRG1) loss-of-function mutations enriched in lung adenocarcinoma (~10%), small-cell carcinoma of the ovary hypercalcemic type (SCCOHT, near-universal SMARCA4 loss), undifferentiated thoracic SMARCA4-deficient sarcomas (near-universal), and subsets of melanoma, colorectal, gastric, and pancreatic cancers. The therapeutic logic for SMARCA2 (BRM) inhibition is paralog synthetic lethality — SMARCA4-deficient tumors become uniquely dependent on SMARCA2 to maintain BAF complex function, allowing selective tumor cell killing while sparing normal SMARCA4-intact tissue. The U.S. addressable population for SMARCA4-mutant solid tumors is approximately 30,000-50,000 patients annually, with NSCLC (lung adenocarcinoma) representing the largest subset at ~25,000 SMARCA4-mutant cases per year. Foghorn's FHD-286 (Phase 1) and FHD-609 (BRD9 degrader for synovial sarcoma) anchor the lead pipeline; the Lilly collaboration extends Foghorn's chromatin-regulator chemistry into oncology programs that include both BRM (SMARCA2) selectivity and three undisclosed discovery targets, with rare-tumor and synthetic-lethal mechanisms as the commercial wedge.
The chromatin-remodeling oncology landscape is led by EZH2 inhibition (Tazverik/tazemetostat, Epizyme/Ipsen — approved 2020 for epithelioid sarcoma and follicular lymphoma), DOT1L inhibition (pinometostat — discontinued), and emerging selective BRD9 degraders, BRM/SMARCA2 inhibitors, and PRC2 modulators. Foghorn's FHD-286 (selective SMARCA2/SMARCA4 dual inhibitor) is in Phase 1 in uveal melanoma and AML; FHD-609 (BRD9 selective degrader, synovial sarcoma) is in Phase 1; Plexium and Prelude Therapeutics are advancing competing BRM/SMARCA2 selective inhibitors and BRM-targeted PROTAC degraders; Roche/Genentech, AstraZeneca, and Novartis all maintain internal chromatin-regulator programs. The Lilly collaboration positions Foghorn alongside Lilly's broader oncology portfolio (Verzenio, Jaypirca, Retevmo, Cyramza) and gives Lilly optionality across multiple chromatin-regulator MOAs at a fraction of acquisition economics. In January 2022, Foghorn paused FHD-286 dosing in AML following an unexpected differentiation-syndrome safety signal, reactivating in 2023 with revised dosing — a development risk that must be reconciled against the deal's discovery-stage milestone economics.
The Lilly/Foghorn collaboration cleared the HSR waiting period and became effective in January 2022, when Foghorn received the $300M cash upfront and $80M equity investment.
Six weeks after the Lilly deal, Foghorn voluntarily paused FHD-286 dosing in AML after two suspected differentiation-syndrome cases; the uveal melanoma Phase 1 continued. Shares fell sharply.
Foghorn dosed the first patient with FHD-909 (LY4050784), a first-in-class oral selective SMARCA2 (BRM) inhibitor, in a Phase 1 trial for SMARCA4-mutated solid tumors (NSCLC primary) — a key milestone for the Lilly collaboration and its new anchor asset.
Phase 1 FHD-286 + decitabine in R/R AML showed responses but missed Foghorn's internal efficacy threshold; Foghorn discontinued independent development and prioritized its proprietary pipeline and the Lilly collaboration (FHD-909). Original anchor asset dropped; collaboration thesis now rests on the FHD-909 SMARCA2 program. Cash of $267.4M (Sept 30, 2024) funds operations into 2027.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Foghorn Therapeutics Inc. (this deal) | 2021 | $1.7B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2021 deals · Eli Lilly and Company deals · Oncology deals